ORLANDO, Florida, May 6th, 2020– Aspire Health Science, LLC (the “Company” or “Aspire”), an FDA registered GMP manufacturing facility specialized in the research, development, and manufacturing of cell-based therapies, is pleased to announce a collaboration with NeoProgen, Inc.
NeoProgen, a Baltimore-based company led by Medtech entrepreneur Bill Niland, is a preclinical stage therapeutics company specializing in the development of novel cellbased cardiac therapies for heart regeneration. Similar to Mr. Niland’s earlier venture with Harpoon Medical, NeoProgen has origins in research at the University of Maryland, Baltimore. That is where Dr. Sunjay Kaushal, a leading pediatric cardiac surgeon, discovered that a specific kind of neonatal cardiac progenitor/ stem cells (nCPCs), obtained from discarded cardiac tissue biopsies, are extremely effective in regenerating muscle tissue in the heart. [Read more…]
